BioAge, positive debut on Nasdaq
BioAge Labs Inc., an American clinical-stage biotechnology company that develops therapies for obesity and metabolic diseases, raised approximately $200 million through its initial public offering (IPO) held last week on the US market, fiercebiotech.com reports.